Aspargo Labs, Inc. (AAGO)
| Market Cap | n/a |
| Revenue (ttm) | 102,654 |
| Net Income (ttm) | -22.36M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AAGO
Aspargo is a commercial stage specialty pharmaceutical and med-tech company focused on designing, developing and marketing proprietary, oral liquid suspension formulations of leading oral solid dose prescription and over-the-counter medications dispensed through “smart”, digitally connected, container closure drug delivery systems and associated mobile apps. Our first commercial product, Sildenafil Oral Suspension, indicated for the treatment of erectile dysfunction (ED), is an oral liquid suspension formulation of sildenafil citrate, administe... [Read more]
News
Aspargo Labs IPO Registration Document (S-1)
Aspargo Labs has filed to go public with an IPO on the New York Stock Exchange (NYSE).
Erectile dysfunction drug formulation maker Aspargo Labs files for a direct listing on the NYSE
Aspargo Labs, which makes an oral liquid suspension formulation of a drug for erectile dysfunction, filed on Friday to register its shares with the SEC and complete a direct listing on the NYSE.